Ampa Health develops transcranial magnetic stimulation (TMS) technology to treat depression and other mental and neurological disorders. The company was founded in 2022 and focuses on making brain stimulation therapy more accessible and scalable through innovations in neuromodulation and medical device design.
The company's primary product is Ampa One, an FDA-cleared TMS system designed as a lightweight, portable platform for clinical use. The device delivers magnetic pulses to activate and strengthen specific brain circuits through neuroplasticity, offering a non-invasive treatment approach. Ampa One was built with input from clinicians to address practical workflows in clinical settings.
Ampa Health operates in the medical device and mental health sectors, with regulatory clearance in the United States. The company's stated mission is to help one billion people reach remission from mental and neurological disorders, positioning itself within a broader context where over 3 million patients have historically received more than 60 million TMS treatments globally.
